VISUAL INFORMATION PROCESSING EVALUATION AND ORTHOPTIC AND VISION THERAPY

Policy Number: VISION 011.17 T1

Effective Date: November 1, 2017

Table of Contents

INSTRUCTIONS FOR USE ............................................. 1
CONDITIONS OF COVERAGE ...................................... 1
BENEFIT CONSIDERATIONS ....................................... 1
COVERAGE RATIONALE ............................................... 2
APPLICABLE CODES .................................................. 2
DESCRIPTION OF SERVICES ........................................ 3
CLINICAL EVIDENCE .................................................. 3
U.S. FOOD AND DRUG ADMINISTRATION .................... 13
REFERENCES .......................................................... 14
POLICY HISTORY/REVISION INFORMATION .................. 16

INSTRUCTIONS FOR USE

This Clinical Policy provides assistance in interpreting Oxford benefit plans. Unless otherwise stated, Oxford policies do not apply to Medicare Advantage members. Oxford reserves the right, in its sole discretion, to modify its policies as necessary. This Clinical Policy is provided for informational purposes. It does not constitute medical advice. The term Oxford includes Oxford Health Plans, LLC and all of its subsidiaries as appropriate for these policies.

When deciding coverage, the member specific benefit plan document must be referenced. The terms of the member specific benefit plan document [e.g., Certificate of Coverage (COC), Schedule of Benefits (SOB), and/or Summary Plan Description (SPD)] may differ greatly from the standard benefit plan upon which this Clinical Policy is based. In the event of a conflict, the member specific benefit plan document supersedes this Clinical Policy. All reviewers must first identify member eligibility, any federal or state regulatory requirements, and the member specific benefit plan coverage prior to use of this Clinical Policy. Other Policies may apply.

UnitedHealthcare may also use tools developed by third parties, such as the MCG™ Care Guidelines, to assist us in administering health benefits. The MCG™ Care Guidelines are intended to be used in connection with the independent professional medical judgment of a qualified health care provider and do not constitute the practice of medicine or medical advice.

CONDITIONS OF COVERAGE

Applicable Lines of Business/ Products

This policy applies to Oxford Commercial plan membership.

Benefit Type

General benefits package

Referral Required

Yes

(Does not apply to non-gatekeeper products)

Authorization Required

No

(Precertification always required for inpatient admission)

Pre-certification with Medical Director Review Required

No

Applicable Site(s) of Service

Office

(If site of service is not listed, Medical Director review is required)

BENEFIT CONSIDERATIONS

Before using this policy, please check the member specific benefit plan document and any federal or state mandates, if applicable.
Essential Health Benefits for Individual and Small Group

For plan years beginning on or after January 1, 2014, the Affordable Care Act of 2010 (ACA) requires fully insured non-grandfathered individual and small group plans (inside and outside of Exchanges) to provide coverage for ten categories of Essential Health Benefits (“EHBs”). Large group plans (both self-funded and fully insured), and small group ASO plans, are not subject to the requirement to offer coverage for EHBs. However, if such plans choose to provide coverage for benefits which are deemed EHBs, the ACA requires all dollar limits on those benefits to be removed on all Grandfathered and Non-Grandfathered plans. The determination of which benefits constitute EHBs is made on a state by state basis. As such, when using this policy, it is important to refer to the member specific benefit plan document to determine benefit coverage.

Coverage Rationale

Occlusion therapy is proven and medically necessary for treating amblyopia (lazy eye).

Prism adaptation therapy is proven and medically necessary for treating esotropia (a form of strabismus when the eye deviates inward).

Orthoptic or vision therapy is proven and medically necessary for treating convergence insufficiency (ability of eyes to fix on the same point).

Orthoptic or vision therapy is unproven and not medically necessary for treating the following:
- Exotropia (eye deviates outward) without convergence insufficiency
- Nystagmus (involuntary movement of the eyeballs)
- Convergence excess (esotropia is greater for near vision than for far vision)
- Divergence insufficiency
- Divergence excess
- Stroke or traumatic brain injury with visuospatial deficit, hemispatial neglect, or visual loss

The available data supporting the use of vision therapy for these indications is weak and inconclusive, and derived primarily from uncontrolled or poorly controlled studies with significant methodological flaws.

The use of visual information processing evaluations to diagnose reading or learning disabilities is unproven and not medically necessary.

There is inadequate clinical evidence to support the use of visual information processing evaluations for diagnosing reading or learning-related disabilities. Additional well-designed studies with larger sample sizes are needed to establish the diagnostic utility of this procedure.

Orthoptic or vision therapy including colored lenses, filters, and overlays is unproven and not medically necessary for treating dyslexia and other learning and reading disabilities.

There is a lack of robust data available on the efficacy of orthoptic therapy for treating dyslexia and other reading and learning disabilities. Several small randomized controlled trials of vision therapy have been published, but these studies were flawed by design limitations (including small sample size and poorly defined patient selection criteria). The American Academy of Pediatrics has published a statement that concludes that vision therapy is ineffective for the treatment of learning and reading problems.

Visual perceptual therapy is unproven and not medically necessary for any type of learning disability or language disorder, including developmental delay.

The available data supporting the use of visual perceptual therapy to treat learning or developmental disabilities is weak and inconclusive, and derived primarily from uncontrolled or poorly controlled studies with significant methodological flaws.

Vision restoration therapy is unproven and not medically necessary for treating visual field deficits following stroke or neurotrauma.

There is inadequate evidence of efficacy for this treatment. The number of participants in the few available published studies is small and follow-up time is short.

Applicable Codes

The following list(s) of procedure and/or diagnosis codes is provided for reference purposes only and may not be all inclusive. Listing of a code in this policy does not imply that the service described by the code is a covered or non-covered health service. Benefit coverage for health services is determined by the member specific benefit plan.
Vision therapy is sometimes called eye exercise therapy, visual therapy, visual training, vision training, orthoptic therapy, orthoptics, orthoptic vision therapy, or optometric vision therapy. Vision therapy encompasses a wide range of optometric treatment modalities, with the therapeutic goal of correcting or improving specific dysfunctions of the vision system. There is no clear consensus on the exact definition of vision therapy.

The American Optometric Association (AOA) defines vision therapy as a sequence of neurosensory and neuromuscular activities individually prescribed and monitored by the doctor to develop, rehabilitate and enhance visual skills and processing. The vision therapy program is based on the results of a comprehensive eye examination or consultation, and takes into consideration the results of standardized tests, the needs of the patient, and the patient’s signs and symptoms. The use of lenses, prisms, filters, occluders, specialized instruments, and computer programs is an integral part of vision therapy. The length of the therapy program varies depending on the severity of the diagnosed conditions, typically ranging from several months to longer periods of time. Activities paralleling in-office techniques are typically taught to the patient to be practiced at home, thereby reinforcing the developing visual skills.

These therapies are used for eye movement and fixation training to eliminate or improve conditions such as lazy eye (amblyopia), crossed eyes (strabismus), focusing, eye-teaming, and tracking disorders. Vision therapy is administered in the office under the optometrist's guidance and requires a number of office visits, with the length of the program usually ranging from several weeks to several months, depending on the severity of the diagnosed conditions (Hayes, 2002). For purposes of this policy, orthoptic or vision therapy does not include the use of refractive treatment including refractive lenses.

Visual perceptual therapy is a psychoeducational intervention intended to correct visual-motor or perceptual-cognitive deficiencies that are claimed to contribute to delay in speech and language development in preschool children.

Vision restoration therapy (VRT) targets the vision center of the brain and is intended to improve visual function in patients with visual field deficits that may result from trauma, stroke, inflammation, or elective surgery for removal of brain tumors. Patients utilize a computer screen to focus on a displayed central point and respond every time they see light stimuli appear. The light stimuli are presented in the area most likely to recover visual function, an area which will change as therapy progresses and vision is improved. (Nova Vision, 2007)

Visual information processing evaluation (VIPE) identifies problems with processing of information for enhanced school and/or social development. Visual processing refers to a group of skills used for interpreting and understanding visual information. The evaluation may include testing for visual spatial orientation skills, visual analysis skills, including auditory-visual integration, visual-motor integration skills and rapid naming.

Orthoptics is an allied health profession within the ophthalmic field pertaining to the evaluation and treatment of patients with disorders of the visual system with an emphasis on binocular vision and eye movements. (American Association of Certified Orthoptists website)

### Clinical Evidence

**Vision Therapy for Amblyopia**

Amblyopia, sometimes called lazy eye, is characterized by poor vision in an eye that did not develop normal sight during childhood so that 1 eye develops good vision while the other does not. This condition affects approximately 2% to 3% of the population. There are three major causes of amblyopia: strabismus (misaligned or crossed eyes), unequal focus (a refractive error) and cloudiness in normally clear tissues (such as from cataracts). To correct amblyopia, the patient must be made to use the weak eye. This is accomplished through patching the good eye. This treatment is known as occlusion therapy and is a standard treatment. Atropine sulfate has also been used to blur the good eye. (Kushner, 2002)

In a prospective, randomized, multicenter clinical trial, the Pediatric Eye Disease Investigator Group (PEDIG) (2013) evaluated the effectiveness of increasing prescribed daily patching from 2 to 6 hours in children with stable residual amblyopia. The study group consisted of 169 children aged 3 to <8 years (mean, 5.9 years) with stable residual amblyopia. The study group consisted of 169 children aged 3 to <8 years (mean, 5.9 years) with stable residual amblyopia.
amblyopia (20/32–20/160) who had received 2 hours of daily patching for at least 12 weeks. The main outcome measure was best-corrected visual acuity (VA) in the amblyopic eye after 10 weeks. Ten weeks after randomization, amblyopic eye VA had improved an average of 1.2 lines in the 6-hour group and 0.5 line in the 2-hour group (difference in mean VA adjusted for acuity at randomization = 0.6 line; 95% confidence interval, 0.3–1.0; P = 0.002). Improvement of 2 or more lines occurred in 40% of participants patched for 6 hours versus 18% of those who continued to patch for 2 hours (P = 0.003). The authors concluded that when amblyopic eye VA stops improving with 2 hours of daily patching, increasing the daily patching dosage to 6 hours results in more improvement in VA after 10 weeks compared with continuing 2 hours daily.

Repka et al. (2014) reported visual acuity of patients at 15 years of age who were younger than 7 years when enrolled in a treatment trial for moderate amblyopia. In a multicenter clinical trial, 419 children with amblyopia (visual acuity, 20/40 to 20/100) were randomly assigned to patching (minimum of 6 h/d) or atropine sulfate eyedrops, 1% (1 drop daily), for 6 months. Treatment after 6 months was at the discretion of the investigator. Two years after enrollment, an unselected subgroup of 188 children were enrolled into long-term follow-up. At 15 years of age, most children treated for moderate amblyopia when younger than 7 years have good visual acuity, although mild residual amblyopia is common. The authors found the outcome to be similar regardless of initial treatment with atropine or patching. Better visual acuity at the 15-year examination was achieved in those who were younger than 5 years at the time of entry into the randomized clinical trial (mean logMAR, 0.09) compared with those aged 5 to 6 years (mean logMAR, 0.18; P < .001). When we compared subgroups based on original treatment with atropine or patching, no significant differences were observed in visual acuity of amblyopic and fellow eyes at 15 years of age (P=.44 and P=.43, respectively). The authors concluded that the results indicate that improvement occurring with amblyopia treatment is maintained until at least 15 years of age.

In a randomized controlled clinical trial, Rutstein et al. (2010a) evaluated whether visual acuity improvement with Bangerter filters is similar to improvement with patching as initial therapy for children with moderate amblyopia. The study enrolled 186 children, 3 to <10 years old, with moderate amblyopia. Children were randomly assigned to receive either daily patching or to use a Bangerter filter on the spectacle lens in front of the fellow eye. Study visits were scheduled at 6, 12, 18, and 24 weeks. At 24 weeks, amblyopic eye improvement averaged 1.9 lines in the Bangerter group and 2.3 lines in the patching group. The authors concluded that because the average difference in visual acuity improvement between Bangerter filters and patching was less than half a line and there was lower burden of treatment on the child and family, Bangerter filter treatment is a reasonable option to consider for initial treatment of moderate amblyopia. The authors indicated that although the mean difference between groups was only 0.38 line, the end of the confidence interval on the difference was 0.76 line, and thus, treatment with Bangerter filters did not quite meet the prespecified definition of non-inferiority to patching when initiating therapy for moderate amblyopia. However, the authors also did not find that patching was statistically superior to Bangerter filters. Therefore, the authors could not conclude that the Bangerter filter treatment effect is similar to that seen with patching (based on our predefined definition of non-inferiority), but they also could not conclude that patching is definitely better.

In a prospective, randomized clinical trial, Agervi et al. (2010) compared spectacles plus patching 8 hours or more daily 6 days a week with spectacles plus patching 8 hours or more on alternate days to treat amblyopia in 40 children 4 to 5 years of age. The main outcome measure was median change in best corrected visual acuity (BCVA) of the amblyopic eye after 1 year. The median change in BCVA of the amblyopic eye did not differ significantly between the 2 groups. Binocular function improved in both groups with no significant differences between the groups at 1 year. The investigators concluded that the magnitude of change in the BCVA 1 year after spectacles plus prescribed alternate-day patching was not significantly different than that after spectacles plus prescribed daily patching to treat amblyopia in children 4 to 5 years old. The effect of patching was not separate from that of optical correction with a period of refractive adaptation. Thus, the improvement in visual acuity is a combined effect of spectacle wear and occlusion therapy.

A large randomized controlled trial supported by the National Eye Institute involved 419 children. The participants were assigned to either patching or atropine drops as treatment for amblyopia. Visual acuity improved in both groups (79% in the patching group and 74% in the atropine group). Both treatments were well tolerated, but the parents of the atropine treated group reported a slightly higher degree of acceptability. (PEDIG, 2002)

In a meta-analysis of part-time (PTO) versus full-time occlusion therapy (FTO) for treatment of amblyopia, Yazdani et al. (2017) included six studies [three randomized controlled trials (RCTs) and three non-RCTs]. Pooled standardized difference in the mean changes in the visual acuity was 0.337 (lower and upper limits: 0.009, 0.683) higher in the FTO as compared to the PTO group; however, this difference was not statistically significant (P ¼ 0.056, Cochrane Q value ¼ 20.4 (P ¼ 0.001), 12 ¼ 75.49%). Egger's regression intercept was 5.46 (P ¼ 0.04). The pooled standardized difference in means of visual acuity changes was 1.097 (lower and upper limits: 0.68, 1.513) higher in the FTO arm (P < 0.001), and 0.7 (lower and upper limits: 0.315, 1.085) higher in the PTO arm (P < 0.001) compared to PTO less than two hours. The authors concluded that this meta-analysis showed no statistically significant difference between
PTO and FTO in treatment of amblyopia. However, their results suggest that the minimum effective PTO duration, to observe maximal improvement in visual acuity is six hours per day.

Shotton and Elliott (2008) systematically reviewed the available evidence to establish the most effective treatment for strabismic amblyopia. This review aimed to examine the impact of conventional occlusion therapy for strabismic amblyopia and analyze the role of partial occlusion and optical penalization for strabismic amblyopia. Two randomized controlled trials (RCTs) were included in the review. The authors concluded that occlusion, while wearing necessary refractive correction, appears to be more effective than refractive correction alone in the treatment of strabismic amblyopia.

In a Cochrane review, Taylor and Elliott (2014) evaluated the most effective treatment for strabismic amblyopia. The review found that occlusion, while wearing necessary refractive correction, appears to be more effective than refractive correction alone in the treatment of strabismic amblyopia.

**Vision Therapy for Strabismus**

Strabismus is an ocular misalignment. The most common types are esotropia (inwardly deviating eyes) and exotropia (outwardly deviating eyes). Less common is hypertropia, when one eye turns upward and hypotropia, when one eye turns downward. Prevalence estimates of strabismus range from 1% to 6% in different populations.

Williams et al. (2014) systematically searched 13 databases to evaluate the most effective strategies for treating children with visual and neurodevelopmental problems (VND). The authors found 4450 abstracts from which they identified 107 papers for inclusion. Of these, 42 related to interventions involving a change in visual input or function: 5 controlled trials, 8 before and after studies and 29 case reports. The strongest evidence supported the provision of spectacles to improve distance or near vision. Less strong but suggestive evidence supported vision training/practice routines to improve acuity or oculomotor control including strabismus. The authors indicated that while training programs and environmental modifications may help children with VND, more evidence is needed on type of vision training, optimum duration and age for vision training, and the degree to which improvements are lasting, transfer to other skills/activities or add to quality of life.

**Esotropia**

The goal of strabismus surgery is to align the eyes and permit fusion with a minimum number of operations. Prisms have proposed as a way to more accurately determine the angle of deviation, or the target angle, for strabismus surgery.

The National Eye Institute (NEI) sponsored the Prism Adaptation Study (PAS), a randomized, multicenter, controlled, clinical trial to determine the overall effect of prism adaptation. The PAS defined prism adaptation as the preoperative wearing of Fresnel prisms to offset the angle of esotropia, with adjustment of prism power over time to accommodate buildup to larger angles of esotropia, until fusion is achieved or it is demonstrated that fusion cannot be attained. Prism-adapted surgery refers to surgery for the angle of deviation at which the prism wearer achieves fusion. The study randomized 333 eligible patients who were at least 3 years of age, had no previous eye surgery, and had acquired deviations of 12 to 40 prism diopters. All patients had 20/40 or better visual acuity in each eye, and amblyopic patients underwent occlusion therapy before entry. Two levels of randomization were used. Sixty percent of the patients (n=199) underwent prism adaptation and 40% (n=134) did not. Those who did not have prism adaptation underwent conventional surgery for their entry angle of deviation. Of those who responded to prisms with motor stability and sensory fusion (n=131), half (n=67) underwent a conventional amount of surgery, i.e., surgery for angle at entry, and half (n=64) underwent augmented surgery based on the prism-adapted angle of deviation. A successful outcome was defined as a deviation of less than or equal to 8 prism diopters of esotropia or exotropia. Success rates 6 months after surgery were highest in prism adaptation responders who underwent augmented surgery and lowest in patients who did not undergo prism adaptation (89% versus 72%). The estimated overall rate of success for patients who went through the prism adaptation process was significantly better than the success rate of patients who did not undergo prism adaptation but underwent surgery for their deviation at entry into the study (83% versus 72%). The investigators concluded that there was a beneficial overall effect of the prism adaptation process for patients with acquired esotropia. (PAS, 1990)

A second report included the 1-year motor and sensory outcomes for patients enrolled in the PAS. Of the 333 patients originally randomized in the study, 305 (92%) completed the 1-year postoperative follow-up. The overall 1-year motor success rate for all patients in the study was 74%. The authors concluded that prism adaptation identifies those patients who can undergo enhanced or augmented surgery without increasing the risk of overcorrection. (Repka, 1996)

In a retrospective review, Quigley et al. (2017) evaluated the prism adaptation test (PAT) response and postoperative outcomes in a cohort of children with accommodative esotropia who underwent bilateral medial rectus recession. The authors reported that 36% of patients showed a requirement for increase of prism dosage to retain orthotropia during PAT; these patients did better than those whose deviation was stable, with postoperative rate of motor success...
(defined as ≤10Δ esotropia) of 100% versus 56%. PAT may be a useful positive prognostic test, and it also identifies a substantial patient population who may avoid undercorrection, the prism builders. The authors suggest that additional randomized studies are required to demonstrate definitive benefit of PAT.

Exotropia

According to Shin et al. (2017), although non-surgical treatments (including occlusion therapy) have limitations as a single treatment for intermittent exotropia, surgery in combination with preoperative occlusion therapy has been found to more effective in reducing exodeviation and has shown a superior success rate compared to that of surgery alone. The authors conducted a retrospective review to determine the effect of preoperative part-time occlusion therapy on long-term surgical success in early-onset exotropia in 51 consecutive patients. The mean duration of preoperative occlusion therapy was 10.2 ± 5.4 months (range, 6 to 28 months). The mean follow-up duration after surgery for exotropia was 78.0 ± 28.1 months (range, 36 to 135 months). Overall, the final success rate of surgery for early-onset exotropia was 66.7%. Five patients (9.8%) showed persisting consecutive esotropia and eventually underwent surgical correction for these consecutive esotropia at a mean age of 18.8 months (range, 8 to 40 months) after the primary surgery for exotropia. A higher long-term success and lower recurrence rate was found in patients who were deemed as compliant (>50%) than in the group of patients who were deemed to be non-compliant (<50%).

Since evidence of effectiveness of interventions for treatment of childhood intermittent exotropia is unclear, Joyce et al. (2015) conducted a systematic review to locate, appraise and synthesize evidence of effectiveness. The authors included randomized controlled trials, quasi-experimental and cohort studies with a comparison group examining interventions for divergence excess, simulated divergence excess or basic type exotropia in children, up to and including 18 years of age, followed for at least 6 months. Dual data extraction and critical appraisal were conducted and a narrative synthesis undertaken. Eleven studies satisfied the eligibility criteria. Seven examined the comparative effectiveness of two surgical procedures; four compared surgery with other interventions, including botulinum toxin A therapy, orthoptic exercises, occlusion, binocular vision training and watchful waiting. The evidence retrieved was of limited extent and quality with differences across studies in terms of outcome assessment and most appropriate time-point for measuring long-term outcomes. There were mixed outcomes when comparing unilateral recession/resection (R&R) with bilateral lateral rectus recession (BLR) on improving angle of deviation, which makes it difficult to recommend either surgical option with confidence. While non-surgical interventions appear less effective in terms of improving angle of deviation, they are rarely associated with adverse outcomes. The authors concluded that given the limited evidence base, better designed studies are required to address the question of the most effective management for treatment of childhood exotropia. Importantly, consensus is required on what constitutes a successful outcome as well as agreement on how this should be measured.

The Pediatric Eye Disease Investigator Group (PEDIG) conducted a randomized controlled trial to compare part-time patching with observation for previously untreated intermittent exotropia (IXT) in children 12-35 months old (n=201). Participants were randomly assigned to either observation (no treatment for 6 months) or patching prescribed for 3 hours daily for 5 months, followed by 1 month of no patching. The authors reported deterioration (defined as constant exotropia measuring at least 10Δ at distance and near or receipt of non-protocol treatment for IXT) over 6 months was uncommon, with or without patching treatment. There was insufficient evidence for the authors to recommend part-time patching for the treatment of IXT in children in this age group. (Mohney et al., 2015)

Gnanaraj and Richardson (2005) conducted a systematic review to clarify the effects of various surgical and nonsurgical treatments for management decisions in intermittent distance exotropia. No randomized controlled trials were found that met selection criteria. The authors found that the current literature consists mainly of retrospective reviews and these are difficult to compare and analyze due to variations in definition, intervention criteria, and outcome measures. Data from individual studies on suggested intervention criteria were found to be variable, although there was some consistency in suggesting that small-angle deviations (less than 20 prism diopters) may be improved by nonsurgical treatments such as exercising fusion, eliminating suppression, or inducing accommodation using minus lenses. According to the authors, the efficacy of these treatments remains debatable.

Hatt and Gnanaraj (2013) analyzed the effects of various surgical and non-surgical treatments in randomized trials of people with intermittent exotropia, to report intervention criteria and determine the significance of factors such as age with respect to outcome. The authors searched for randomized controlled trials of any surgical or non-surgical treatment for intermittent exotropia. One randomized trial was eligible for inclusion in the review. This trial showed that unilateral surgery was more effective than bilateral surgery for correcting basic intermittent exotropia. According to the authors, measures of severity and criteria for intervention were poorly validated for all identified studies. The authors concluded that there is a need for improved measures of severity, a better understanding of the natural history and carefully planned clinical trials of treatment to improve the evidence base for the management of this condition.

Buck et al (2012) investigated the current patterns of management and outcomes of intermittent distance exotropia in an observational cohort study which recruited 460 children aged < 12 years with previously untreated distance
exotropia. Data collected included angle, near stereoacuity, visual acuity, control of distance exotropia measured with the Newcastle Control Score (NCS), and treatment. The main outcome measures were change in clinical outcomes in treated and untreated distance exotropia, 2 years from enrolment (or, where applicable, 6 months after surgery). At follow-up, data were available for 371 children (81% of the original cohort). Of these: 53% (195) had no treatment; 17% (63) had treatment for reduced visual acuity only (pure refractive error and amblyopia); 13% (50) had no-surgical treatment for control (spectacle lenses, occlusion, prisms, exercises) and 17% (63) had surgery. Only 0.5% (2/371) children developed constant exotropia. The surgically treated group was the only group with clinically significant improvements in angle or NCS, but rates of overcorrection are high. Non-surgical treatment of intermittent distance exotropia had less significant impact on angle of deviation or scores on the NCS.

**Vision Therapy for Convergence Insufficiency With or Without Accommodative Disorders**

In a systematic review of the literature on orthoptic therapy for convergence insufficiency, Rucker and Phillips (2017) reported that convergence exercises reduce symptoms and improve signs of CI in otherwise healthy patients. However, the most efficacious convergence tasks and the optimal duration and frequency of these tasks, remain unknown. The authors did not identify randomized, controlled studies that show treatment consisting of repetitive ocular motor tasks improves learning disabilities, reading, dyslexia, or ADHD.

Scheiman et al. (2011a) systematically assessed and synthesized evidence from randomized controlled trials (RCTs) on the effectiveness of non-surgical interventions for convergence insufficiency. The review included six trials (three in children, three in adults) with a total of 475 participants. The authors concluded that for children, office-based vision therapy is more effective than home-based convergence exercises (i.e., pencil push-ups) or home-based computer vision therapy. The evidence of the effectiveness of nonsurgical treatments of CI in adults was considered less consistent.

Cacho Martinez et al. (2009) conducted a systematic review of reports published from 1986 to 2007 to analyze the scientific evidence available on the nonsurgical treatment of accommodative and non-strabismic binocular dysfunctions, identifying the types of treatment used and their efficacy. Of the 565 articles identified, 16 met the inclusion criteria. Only 3 were clinical trials. All analyzed treatment of convergence insufficiency. Results of clinical trials support the conclusion that vision therapy improves symptoms and signs for convergence insufficiency. Further, the evidence indicates that pencil push-up treatment is not as effective as vision therapy and that prism glasses are no more effective than placebo glasses. For the other non-strabismic binocular conditions and accommodative disorders, there is a lack of published randomized, clinical trials that support the evidence for the efficacy of each treatment.

Rawstron et al. published a systematic review of eye exercises in 2005. The review concluded that small controlled trials and many case reports support the use of eye exercises in the treatment of convergence insufficiency. However, there was no clear evidence supporting the use of eye exercises for other vergence disorders, myopia, amblyopia, accommodative dysfunction, and learning disabilities and dyslexia; thus, their use for these indications remains controversial.

The National Eye Institute (NEI) sponsored the Convergence Insufficiency Treatment Trial (CITT) study, a randomized controlled trial comparing the effectiveness of different treatment options for convergence insufficiency (CI) in 221 children (age 9 to 17 years). Three types of vision therapy were compared with a placebo therapy intervention. Vision therapy included: (1) office-based vision therapy with at-home exercises; (2) home-based pencil push-ups with additional computer vision therapy; and (3) home-based pencil push-up therapy alone. The placebo therapy group was given placebo vision activities that simulated office-based therapy. The study found that after 12 weeks of treatment, nearly 75% of children who received office-based vision therapy with at-home reinforcement achieved normal vision or had significantly fewer symptoms of CI. In comparison, only 43% of patients who completed home-based therapy alone showed similar results, as did 33% of patients who used home-based pencil push-ups with computer therapy, and 35% of patients who underwent office-based placebo therapy (NEI 2008).

Shin et al. (2011) conducted a prospective controlled trial comparing office-based vision therapy with no vision therapy treatment. The study included 57 children aged 9-13 years who were diagnosed with symptomatic CI (n = 27) or combined symptomatic CI and accommodation insufficiency (AI) (n = 30). They were independently divided into a treatment and a control group, matched by age and gender. Office-based vision therapy significantly improved symptoms and clinical signs including NPC, PFV, mean accommodative amplitude, and mean accommodative facility relative to no treatment in children with CI and accommodative insufficiency. Of the patients with concurrent CI and accommodative insufficiency who received vision therapy, 77% were considered improved and 61% were considered cured. Of the 11 patients who completed the 1-year follow-up, symptom scores had deteriorated to abnormal levels in 2 children and 1 child also showed regression of the NPC. The authors concluded that this study supports the use of vision therapy as a successful method of treating CI and CI combined with AI.
In a randomized clinical trial, Scheiman et al. (2011b) assessed the effectiveness of various types of vision therapy for improving accommodative amplitude or accommodative facility in 221 children with deficiencies in these measures at baseline. All types of vision therapy (i.e., office-based vision therapy, HBCVAT+, and HBPP) were superior to office-based placebo vision treatment for improving mean accommodative amplitude. With regard to accommodative facility, only the office-based vision therapy group exhibited a significantly greater improvement than the placebo group. This study did not report the results of symptoms or other clinical signs. One year after completion of therapy, reoccurrence of decreased accommodative amplitude was present in only 12.5% and accommodative facility in only 11%. The authors concluded that vision therapy/orthoptics is effective in improving accommodative amplitude and accommodative facility in school-aged children with symptomatic CI and accommodative dysfunction.

Vision Therapy for Nystagmus
No well-designed clinical trials that support the use of vision therapy for nystagmus were identified.

Vision Therapy for Convergence Excess
Convergence excess is a sensorimotor anomaly of the binocular vision system, characterized by a tendency for the eyes to overconverge at near.

To evaluate the effectiveness of vision therapy for convergence excess, a common ocular motility disorder, Gallaway and Scheiman (1997) retrospectively reviewed the records of 83 consecutive patients with this condition, seen in two private practices over a 3-year period and treated with vision therapy. The mean age of subjects was 11.8 years, with a range of 7 to 32 years. Therapy consisted of once- or twice weekly 45-minute office visits, and home therapy for 15 minutes 3 to 4 times per week. The mean number of vision therapy sessions was 18.5, with a range of 9 to 32. The investigators observed statistically and clinically significant changes in direct and indirect measures of negative fusional vergence, with 84% of patients reporting a total elimination of initial symptoms. The design of the study, a retrospective case series, and possible patient selection bias limit the value of these findings.

Vision Therapy for Divergence Insufficiency
No well-designed clinical trials evaluating the use of vision therapy for divergence insufficiency were identified.

Vision Therapy for Convergence Excess
No well-designed clinical trials evaluating the use of vision therapy for divergence excess were identified.

Vision Therapy for Stroke and Traumatic Brain Injury
Hunt et al. (2016) conducted a systematic review of evidence regarding the use of oculomotor-based vision assessment to identify and monitor recovery from mild traumatic brain injury (mTBI). Their objectives were to (1) identify changes in oculomotor-based vision following mTBI; (2) distinguish methods of assessment; (3) appraise the level and quality of evidence; and, if warranted, (4) determine clinical recommendations for assessment. Articles were included if study populations were clearly identified as having mTBI and used an assessment of oculomotor-based vision. 20 articles met their inclusion criteria (study populations were clearly identified as having mTBI and used an assessment of oculomotor-based vision.). Exploratory findings suggest that measurements of saccades, smooth pursuit, and vergence are useful in detecting changes associated with mTBI. Assessment methods included eye tracker protocols, optometric assessment, and the King-Devick test. The authors noted that the strength of this evidence is not yet sufficient to warrant clinical recommendations. Research using rigorous methods is required to develop reliable, valid, and clinically useful assessment protocols.

An overlap of investigators and, presumably, overlap of study participants were found for several studies evaluating vision therapy after traumatic brain injury. Three randomized controlled trials by the same primary author appeared to be reporting data for different endpoints on the same study group (Thiagarajan and Ciuffreda, 2014; Thiagarajan et al., 2014; Thiagarajan and Ciuffreda, 2013). These trials showed improvement with the use of vision therapy but evaluated only 12 patients.

van Wyk et al. (2014) evaluated the effect of saccadic eye movement training with visual scanning exercises (VSEs) integrated with task-specific activities on unilateral spatial neglect (USN) poststroke. A matched-pair randomized control trial was conducted. Subjects were matched according to their functional activity level and allocated to either a control (n = 12) or an experimental group (n = 12). All patients received task-specific activities for a 4-week intervention period. The experimental group received saccadic eye movement training with VSE integrated with task specific activities as an "add on" intervention. Assessments were conducted weekly over the intervention period. Statistical significant difference was noted on the King-Devick Test (P = .021), Star Cancellation Test (P = .016), and Barthel Index (P = .004). The authors concluded that intensive saccadic eye movement training with VSE integrated with task-specific activities has a significant effect on USN in patients poststroke. Long-term follow-up and further studies with larger patient populations are needed to verify these results.
Mizuno et al. (2011) conducted a multicenter, double-masked, randomized, controlled trial to evaluate the effects of a 2-week prism adaptation (PA) therapy on unilateral spatial neglect (USN)). A total of 38 USN patients with right-brain damage were divided into prism (n = 20) and control (n = 18) groups. Patients were divided into mild and severe USN groups according to Behavioral Inattention Test (BIT) parameters (mild ≥ 55 and severe<55). The prism group performed repetitive pointing with prism glasses that induce rightward optical shift twice daily, 5 days per week, for 2 weeks, whereas the control group performed similar pointing training with neutral glasses. The Functional Independence Measure (FIM) improved significantly more in the prism group. In mild USN patients, there was significantly greater improvement of BIT and FIM in the prism group. The authors concluded that PA therapy can significantly improve ADL in patients with subacute stroke. These findings require confirmation in a larger study.

In a systematic review of interdisciplinray literature, Klinke et al. (2015) identified rehabilitation interventions that can be integrated into ward-based nursing for patients with hemispatial neglect following stroke in the right brain hemisphere. Using 41 original studies, 11 interventions were identified. The selected studies were graded according to the strength of their evidence (Levels 1-5); the proposed interventions were given recommendation grades (Grades A-D). The interventions included right half-field eye patching (Grade D), smooth pursuit eye-movement training (Grade B) and visual scanning training (Grade D). The authors noted that there was general low level of evidence and the diversity of interventions which made it difficult to endorse specific priorities and combinations for implementation.

In a Cochrane review, Pollock et al. (2011) determined the effects of interventions for visual field defects after stroke. Thirteen studies (344 randomized participants, 285 of whom were participants with stroke) met the inclusion criteria for this review. However, only six of these studies compared the effect of an intervention with a placebo, control or no treatment group and were included in comparisons within this review. The authors concluded that there is insufficient evidence to reach generalized conclusions about the benefits of visual prisms (substitutive intervention) for patients with visual field defects after stroke.

In a single blinded pilot randomized controlled trial, Turton et al. (2010) evaluated the feasibility of delivering prism adaptation treatment in a clinically valid sample and assessed its impact on self-care in 37 right hemisphere stroke patients with unilateral spatial neglect. The patients were randomized into either prism adaptation (using 10 diopter, 6 degree prisms) or sham treatment (using plain glasses) groups. Treatment was delivered each weekday for two weeks. Thirty four patients received treatment: 16 with prisms, 18 with sham treatment. Mean compliance was 99% and 97%, respectively. Over the treatment days only the prism treated group showed increased leftward bias in open loop pointing to targets on a touch screen. However, despite the group level changes in pointing behavior no overall effect of the treatment on self-care or Behavioral Inattention Test (BIT) were found.

A National Institute for Health and Care Excellence (NICE) guidance document (2013) states that eye movement therapy can be offered to people who have persisting hemianopia after stroke and who are aware of the condition. This recommendation was based on 3 randomized controlled trials, the confidence level of results ranging from very low to moderate.

**Vision Therapy for Dyslexia and Other Reading and Learning Disabilities**

Dyslexia is a neuro-developmental condition that causes reading difficulties in 5% to 10% of children. A deficiency in processing linguistic units (phonemes) that make up written and spoken words is believed to be the major etiologic factor for dyslexia. Proponents of vision therapy hypothesize that many dyslexics have impaired development of the magnocellular component of the visual system, which is important for timing visual events and controlling eye movements. They believe that poor control of eye movement may cause unstable binocular fixation with unsteady vision and may explain why some patients report that the words move around the page. (Stein, 2000)

Hall et al. (2013) conducted a randomized, double blind trial with 73 delayed readers to compare changes in reading and spelling as well as irregular and non-word reading skills after 3 months of wearing either the Harris or the Dyslexia Research Trust (DRT) filters. Reading improved significantly after wearing either type of filter, with 40% of the children improving their reading age by 6 months or more during the 3 month trial. However, spelling ability and non-word reading improved significantly more with the DRT than with the Harris filters. The authors concluded that education and rehabilitation professionals should consider colored filters as an effective intervention for delayed readers experiencing visual stress. According to the authors, this research will help to support the use of colored filters for visual reading capacity but further more rigorous research is needed.

In a double-masked, placebo crossover randomized controlled trial, Ritchie et al. (2011) tested the efficacy of Irlen colored overlays for alleviating reading difficulties thought to have been caused by Irlen syndrome, a proposed perceptual disorder with controversial diagnostic status. Sixty-one school children (aged 7-12 years) with reading difficulties were included in the study. Based on the study results, the authors concluded that Irlen colored overlays do not have any demonstrable immediate effect on reading in children with reading difficulties.
Visual Perceptual Therapy

In a prospective study, Yalcin and Balci (2014) evaluated the efficacy of neural vision therapy, also known as perceptual vision therapy, in enhancing best corrected visual acuity (BCVA) and contrast sensitivity function in amblyopic patients. The study enrolled 99 subjects (age 9 to 50 years) previously diagnosed with unilateral hypermetropic amblyopia. The subjects were divided into two groups, with 53 subjects (53 eyes) in the perceptual vision therapy group and 46 subjects (46 eyes) in the control group. Because the nature of the treatment demands hard work and strict compliance, the minimal number of subjects required to achieve statistically significant results were enrolled. Study phases included a baseline screening, a series of 45 training sessions with perceptual vision therapy, and an end-of-treatment examination. BCVA and contrast sensitivity function at 1.5, 3, 6, 12, and 18 cycles per degree spatial frequencies were obtained for statistical analysis in both groups. All subjects had follow-up examinations within 4-8 months. With the exception of one subject from the study group and two subjects from the control group, all subjects had occlusion during childhood. The study was not masked. The results for the study group demonstrated a mean improvement of 2.6 logarithm of the minimum angle of resolution (logMAR) lines in visual acuity (from 0.42 to 0.16 logMAR). Contrast sensitivity function improved at 1.5, 3, 6, 12, and 18 cycles per degree spatial frequencies. The control group did not show any significant change in visual acuity or contrast sensitivity function. None of the treated eyes showed a drop in visual acuity. The authors concluded that the results of the study demonstrate the efficacy of perceptual vision therapy in improving visual acuity. According to the authors, long-term follow-up and further studies are needed to verify these results.

The available data regarding visual perceptual therapy is relatively weak, inconclusive, and derived primarily from uncontrolled or poorly controlled studies with significant methodological flaws. There are no well-designed clinical trials that indicate that visual perceptual therapy is an effective treatment for any type of learning disability or disorder.

Vision Restoration Therapy (VRT)

Vision Restoration Training (VRT) aims at improving lost vision by activating residual visual functions by training light detection and discrimination of visual stimuli. This is accomplished by stimulation of areas of partial injury (represented by partially functioning regions of the visual field) that might induce synaptic plasticity and thus improve lost visual functions. Restoration techniques aim at modifying the visual system itself by lowering the threshold of perception. There has been a vigorous and controversial debate about whether vision restoration is possible at all. (Dundon, et al., 2015)

In a prospective, double-blind, randomized, placebo-controlled clinical trial, Sabel and Gudlin (2014) determined if behavioral activation of areas of residual vision using daily 1-hour vision restoration training for glaucoma for 3 months improved detection accuracy compared with placebo. The study participants included a volunteer sample of patients with glaucoma (mean age, 61.7 years) with stable visual fields and well-controlled intraocular pressure. Study interventions included computer-based vision restoration training for glaucoma (n=15) or visual discrimination placebo training in the intact visual field (n=15). After randomization, 4 patients withdrew from the trial because of mild headaches (n=2) or lack of time to complete the schedule (n=2). The primary end point was change in detection accuracy in high-resolution perimetry. Vision restoration training for glaucoma led to significant detection accuracy gains in high-resolution perimetry, which were not found with white-on-white or blue-on-yellow perimetry. Furthermore, the pre-post differences after vision restoration training for glaucoma were greater compared with placebo in all perimeter tests, and these results were independent of eye movements. Vision restoration training for glaucoma (but not placebo) also led to faster reaction time. Vision-related quality of life was unaffected, but the health-related quality-of-life mental health domain increased in both groups. The authors concluded that visual field defects caused by glaucoma can be improved by repetitively activating residual vision through training the visual field borders and areas of residual vision, thereby increasing their detection sensitivity. According to the authors, this trial revealed evidence that visual field loss is in part reversible by behavioral, computer-based, online controlled vision training, comprising a new rehabilitation treatment option in glaucoma. These findings require confirmation in a larger study with long-term follow-up.

In a systematic review, Dundon et al. (2015) evaluated the rationale underlying treatment paradigms in visual rehabilitation and summarized the available evidence with respect to treatment efficacy. The authors observed that sustained improvements require repetitive stimulation which, depending on the method, may take months. fMRI studies have revealed effects within wider distributed networks, i.e., BOLD changes occur not only in the visual cortex, but also in extrastriate areas. In a similar vein, the notion that treatment improvements driven by VST are exclusively driven by compensatory eye movements has been challenged by some recent experimental findings. They concluded that, broadly speaking, visual rehabilitation targeting restoration of a portion of the visual field, appears to represent an optimal approach to address visual field function and size. However, VRT consists of a long-lasting training protocol, which may not suit the life circumstances of all patients.

In a Cochrane review, Pollock et al. (2011) determined the effects of interventions for people with visual field defects after stroke. Thirteen studies (344 randomized participants, 285 of whom were participants with stroke) met the
inclusion criteria for this review. However, only six of these studies compared the effect of an intervention with a placebo, control or no treatment group and were included in comparisons within this review. The authors concluded that there is insufficient evidence to reach generalized conclusions about the benefits of visual restitution training (VRT) for patients with visual field defects after stroke.

Jung et al. (2008) evaluated the effects of vision restoration therapy (VRT) on the visual function of 10 patients with anterior ischemic optic neuropathy in a randomized controlled double-blind pilot trial. All patients were evaluated before VRT and after 3 and 6 months of treatment by Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity, contrast sensitivity, reading speed, 24-2 SITA-standard Humphrey visual field (HVF), High Resolution Perimetry (HRP) (perimetry obtained during VRT), and vision-based quality of life questionnaire. Patients were randomized between two VRT strategies (5 in each group): I) VRT in which stimulation was performed in the seeing VF of the affected eye ("seeing field-VRT"); II) VRT in which stimulation was performed along the area of central fixation and in the ARV (areas of residual vision) of the affected eye ("ARV-VRT"). The results of the HRP, HVF, and clinical assessment of visual function were compared for each patient and between the two groups at each evaluation. Visual acuity qualitatively improved in the ARV-VRT group, however the change was not statistically significant (p=0.28). Binocular reading speed significantly improved in the ARV-VRT group (p=0.03). HVF foveal sensitivity increased mildly in both groups (p=0.059). HRP analysis showed a similar increase in stimulus accuracy in both groups (mean improvement of about 15%). All patients reported functional improvement after VRT. A small study population limits the conclusions that can be reached from this study.

Mueller et al. (2007) performed a clinical observational analysis of visual fields of 302 patients before and after being treated with computer-based vision restoration therapy for a period of 6 months. The visual field defects were due to ischemia, hemorrhage, head trauma, tumor removal or anterior ischemic optic neuropathy. Primary outcome measure was a visual field assessment with super-threshold perimetry. VRT improved patients' ability to detect super-threshold stimuli in the previously deficient area of the visual field by 17.2% and these detection gains were not significantly correlated with eye movements. Notable improvements were seen in 70.9% of the patients. Efficacy was independent of lesion age and etiology, but patients with larger areas of residual vision at baseline and patients older than 65 years benefited most. Conventional perimetry validated visual field enlargements and patient testimonials confirmed the improvement in every day visual functions. The lack of a control group limits the validity of the results of this study.

**Visual Information Processing Evaluation**

Limited clinical evidence was found to support the use of visual information processing evaluations for diagnosing learning-related or other types of visual deficits.

Goldstand et al. (2005) compared visual and visual-information processing skills between children with and without mild reading and academic problems and examine the incidence of visual deficits among them. Seventy-one seventh graders classified as proficient (n = 46) and non-proficient (n = 25) readers were compared with respect to scores on an accepted vision screening, on tests of visual-perception, visual-motor integration, and academic performance. Further, academic performance and visual-information processing were compared between children who failed and passed the vision screening. Visual deficits were found in 68% of the participants, and among significantly more boys than girls. Non-proficient readers had significantly poorer academic performance and vision-screening scores than the proficient readers. Participants who passed the visual screening performed significantly better in visual perception than those who failed. According to the investigators, visual function significantly distinguishes between children with and without mild academic problems, as well as on visual-perception scores. The investigators concluded that the high occurrence of visual deficits among participants warrants consideration of vision deficits among schoolchildren with academic performance difficulties. These findings require confirmation in a larger study.

**Professional Societies**

**American Academy of Pediatrics (AAP)/Section on Ophthalmology, Council on Children with Disabilities/American Academy of Ophthalmology (AAO)/American Association for Pediatric Ophthalmology and Strabismus (AAPOS)/American Association of Certified Orthoptists (AACO)**

According to a joint policy statement issued by the AAP, AAO, AAPOS, and AACO, diagnostic and treatment approaches for dyslexia that lack scientific evidence of efficacy such as behavioral vision therapy, eye muscle exercises, or colored filters and lenses are not endorsed or recommended. The ophthalmologist should identify and treat any significant visual defect according to standard principles of treatment. Strabismus, ambylopia, and refractive errors may require glasses, eye patching, eye drops, or eye-muscle surgery. In addition, the ophthalmologist should discuss the lack of efficacy of vision therapy and other "alternative treatments" with the parents. (AAP, 2009; reaffirmed 2014)

A 2011 technical report by the AAP, AAO, AAPOS and AACO reinforces the above policy statement. The report indicates that vision problems can interfere with the process of reading, but children with dyslexia or related learning disabilities have the same visual function and ocular health as children without such conditions. Currently, there is
inadequate scientific evidence to support the view that subtle eye or visual problems cause or increase the severity of learning disabilities. According to the report, scientific evidence does not support the claims that visual training, muscle exercises, ocular pursuit-and-tracking exercises, behavioral/perceptual vision therapy, "training" glasses, prisms, and colored lenses and filters are effective direct or indirect treatments for learning disabilities. There is no valid evidence that children who participate in vision therapy are more responsive to educational instruction than children who do not participate. (Handler and Fierson, 2011)

**American Academy of Ophthalmology (AAO)**
In a separate policy statement, the AAO (2013) maintains that children with possible or diagnosed learning disabilities, such as dyslexia, should undergo a comprehensive eye examination so that any undiagnosed vision impairment can be identified and treated. Such children should be referred for appropriate medical, psychological, and educational evaluations and treatment of any learning disability. The organization states that there is insufficient evidence to conclude that "defective eye teaming" and "accommodative disorders" can be underlying causes of educational impairment.

The AAO Preferred Practice Pattern Guidelines (2012a) for the management of esotropia and exotropia indicate that in some patients with acquired esotropia, prisms are used to promote binocular vision and establish the full angle on which to base extraocular muscle surgery. Patients with intermittent exotropia do not typically have diplopia, so prisms are not generally prescribed. However, some patients with intermittent exotropia also have convergence insufficiency. In these cases, base-out prism can be used during convergence exercises. Training in diplopia recognition (antisuppression training) and strengthening vergence amplitudes is ineffective in the treatment of most esotropic patients and may occasionally produce permanent diplopia, especially in patients with monofixation syndrome. In cases of symptomatic convergence insufficiency exotropia that is refractory to exercises, base-in prism can be included in eyeglasses to improve comfort while reading. Orthoptic therapy may improve fusional control in patients with convergence insufficiency exotropia and with small- to moderate-angle exotropia (i.e., 20 prism diopters or less), with the goal of strengthening fusional convergence amplitudes. Patients with the convergence insufficiency type of exotropia (exotropia greater at near) and asthenopic symptoms with near viewing (typically reading) may be good candidates for orthoptic therapy. Near point of convergence exercises on an accommodative target are useful if the near point of convergence is distant. Convergence exercises with a base-out prism may be beneficial once the near point of convergence improves. Treatment is tapered as symptoms improve, and it may need to be resumed if symptoms recur. Other treatments include computer-based convergence exercises and in-office orthoptics.

The AAO Preferred Practice Pattern Guidelines (2012b) for amblyopia recommend that most children who have moderate amblyopia respond to initial treatment consisting of at least 2 hours of daily patching or weekend atropine (strong recommendation, good evidence for treatment of amblyopia) and [discretionary recommendation, good evidence for dosage (amount of time) of treatment].

**American Association for Pediatric Ophthalmology and Strabismus (AAPOS)/American Academy of Ophthalmology (AAO)**
In a joint policy statement, the AAPOS and the AAO state affirm that amblyopia is a medical condition and requires treatment. Amblyopia is typically a preventable and treatable form of vision loss caused by developmental abnormalities of the brain's vision centers. Unless amblyopia is treated promptly during childhood, permanent structural changes occur in the brain, resulting in decreased visual function; recovery of vision in this instance is rarely achieved.

Current methods of preschool vision screening can identify risk factors (primarily high levels of refractive error and anisometropia), that if untreated, increase the likelihood of amblyopia developing. Therefore these amblyopia risk factors should also be considered medical conditions.

Optical correction such as eyeglasses and contacts may be medically indicated as a part of amblyopia treatment in addition to other modalities, such as patching and/or pharmacologic treatment. (AAPOS, AAO; 2002, revised and reaffirmed 2017)

**American Optometric Association (AOA)**
The AOA (2009) issued a clinical care publication on the definition of optometric vision therapy. The document states that research has demonstrated vision therapy can be an effective treatment option for:
- Ocular motility dysfunctions (eye movement disorders)
- Non-strabismic binocular disorders (inefficient eye teaming)
- Strabismus (misalignment of the eyes)
- Amblyopia (poorly developed vision)
- Accommodative disorders (focusing problems)
- Visual information processing disorders, including visual-motor integration and integration with other sensory modalities
The AOA released a revised guideline on Care of the Patient with Strabismus: Esotropia and Exotropia in 2010. (Rutstein et al.) According to the AOA, vision therapy is successful in the treatment of many forms of strabismus. The AOA states that vision therapy or orthoptics involves active training procedures to improve the patient’s fixation ability and oculomotor control, to help eliminate amblyopia, to improve sensory and motor fusion, and to increase facility and the range of accommodation and vergence responses. According to the AOA, the prognosis is most favorable for patients with intermittent strabismus, especially intermittent exotropia, who have sensorimotor fusion at some point in space and those with recently developed strabismus.

The AOA released a revised guideline on care of the patient with accommodative and vergence dysfunction in 2010. (Cooper et al.) According to the guideline, improvement in both accommodative and vergence adaptation systems is the basis of the success of vision therapy. According to the guideline, data is lacking for the efficacy of home-based vision therapy by itself. Home-based vision therapy may be less effective than office-based therapy, as there is no therapist available to provide motivation or correct inappropriate procedures. Therefore, preferred clinical management involves office-based vision therapy in combination with home therapy. The AOA states that therapy combining diplopa awareness with operant-conditioning technique to reinforce alignment in the absence of visual cues has been advocated for divergence excess. The AOA also states that vision therapy is usually successful in patients with divergence insufficiency.

In their clinical guideline on the care of the patient with amblyopia the AOA (Rouse et al., revised 2004) states that the rationale for using occlusion is that occluding the better eye stimulates the amblyopic eye, decreasing inhibition by the better eye. Occlusion enables the amblyopic eye to enhance neural input to the visual cortex. It is also important in eliminating eccentric fixation. However, noncompliance with occlusion represents a significant factor in occlusion failures, especially in patients over 8 years of age in whom up to 50 percent noncompliance is common.

Another treatment option outlined in this guideline is optometric vision therapy or orthoptics, used to correct or improve specific dysfunctions of the vision system. Vision therapy refers to the total treatment program, which may include passive therapy options (e.g., spectacles, occlusion, pharmacologic agents) and active therapy. With such passive treatment options as optical correction and occlusion, the patient experiences a change in visual stimulation without any conscious effort. Active therapy is designed to improve visual performance by the patient’s conscious involvement in a sequence of specific, controlled visual tasks or procedures that provide feedback about the patient’s performance.

Active vision therapy for amblyopia is designed to remediate deficiencies in four specific areas: eye movements and fixation, spatial perception, accommodative efficiency, and binocular function. The goal of vision therapy is remediation of these deficiencies, with subsequent equalization of monocular skills and, finally, integration of the amblyopic eye into binocular functioning. Untreated amblyopic patients are at a greater risk for loss of vision in the better eye.

The AOA clinical practice guideline (Garzia et al., revised 2008) describes learning related vision problems as deficits in two broad visual system components: visual efficiency and visual information processing. Visual efficiency comprises the basic visual physiological processes of visual acuity (and refractive error), accommodation, vergence, and ocular motility. Visual information processing involves higher brain functions including the non-motor aspects of visual perception and cognition, and their integration with motor, auditory, language, and attention systems. Learning related vision problems are the manifestation of deficits in visual efficiency and visual information processing. Visual efficiency problems include uncorrected refractive error, dysfunction of accommodation and vergence control systems and the interaction of these systems, and ocular motility. Accommodative and vergence dysfunctions can be primary deficits or can occur secondary to uncorrected refractive error. Isolated visual efficiency deficits are relatively uncommon; most patients present with multiple deficits.

Correction of refractive error and treatment of visual efficiency dysfunctions can result in improved visual information processing. The treatment of vision information processing deficits usually requires vision therapy, which can begin during the later stages of visual efficiency therapy. This is dependent on associated conditions such as accommodative and vergence dysfunction.

**U.S. FOOD AND DRUG ADMINISTRATION (FDA)**

Vision therapy is a procedure and, as such, is not subject to FDA regulation. Devices used in vision training programs may be classified under a number of different product codes. Some of these devices may be exempt from the 510(k) clearance process. For information on a specific device or manufacturer see the following web site: [http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfPMN/pmn.cfm](http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfPMN/pmn.cfm). (Accessed August 7, 2017)
Nova Vision™, an attention task performance recorder, received FDA 510(k) approval on April 22, 2003. NovaVision™ presents visual stimuli on a computer screen, for the diagnosis and improvement of visual functions in patients with impaired vision that may result from trauma, stroke, inflammation, surgical removal of brain tumors or brain surgery, and may also be used to improve visual function in patients with amblyopia. Additional information is available at: http://www.accessdata.fda.gov/cdrh_docs/pdf2/K023623.pdf. (Accessed August 7, 2017)

REFERENCES

The foregoing Oxford policy has been adapted from an existing UnitedHealthcare national policy that was researched, developed and approved by UnitedHealthcare Medical Technology Assessment Committee. [2017T0072P]


**POLICY HISTORY/REVISION INFORMATION**

<table>
<thead>
<tr>
<th>Date</th>
<th>Action/Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>11/01/2017</td>
<td>Updated supporting information to reflect the most current description of services, clinical evidence, and references; no change to coverage rationale or list of applicable codes</td>
</tr>
<tr>
<td></td>
<td>Archived previous policy version VISION 011.16 T1</td>
</tr>
</tbody>
</table>